Eli Lilly: CHMP recommends migraine drug Rayvow

(CercleFinance.com) - Eli Lilly shares closed up over 4% on Friday after the European CHMP gave a favourable recommendation to Rayvow, its migraine drug.


The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended Rayvow (lasmiditan) for the treatment of migraine in adults,

The committee says that about 15% of the EU population suffer from migraine.



Copyright (c) 2022 CercleFinance.com. All rights reserved.